COHERUS BIOSCIENCES INC. - COMMON STOCK

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

08 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

13 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

05 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Coherus Completes Divestiture of Ophthalmology Franchise

04 Mar 2024 01:00:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

23 Feb 2024 17:33:13 By Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

21 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

05 Feb 2024 08:00:01 By Nasdaq GlobeNewswire

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

22 Jan 2024 01:15:00 By Nasdaq GlobeNewswire

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

18 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 09:00:00 By Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of LOQTORZI™

02 Jan 2024 08:29:00 By Nasdaq GlobeNewswire

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

26 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

11 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces CFO Transition Plans

07 Dec 2023 17:55:48 By Nasdaq GlobeNewswire

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

06 Dec 2023 04:00:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

28 Nov 2023 11:16:23 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

06 Nov 2023 16:07:41 By Nasdaq GlobeNewswire

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

03 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Participate at Upcoming November Investor Conferences

02 Nov 2023 20:00:08 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

30 Oct 2023 18:00:00 By Nasdaq GlobeNewswire